# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0001493152-23-003631
**Filing Date:** 2023-2
**Character Count:** 5821
**Document Hash:** 45c11eaa563fcd5e6e1a5124d9a9b1dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-003631.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001493152-23-003631

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230206

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39531
- **FILM NUMBER:** 23588419

**BUSINESS ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 6, 2023**

**PROCESSA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39531** | **45-1539785** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**7380 Coca Cola Drive, Suite 106**

**Hanover, Maryland, 21076**

(Address of principal executive offices)

**(443) 776-3133**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(b)of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock: Par value $.0001 | PCSA | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Information.**

***Termination of ATM Prospectus Supplement***

On February 6, 2023, Processa Pharmaceuticals, Inc. (the "Company") terminated the prospectus supplement (the "ATM Prospectus Supplement") related to the Company's common stock, par value $0.0001 per share (the "ATM Shares"). On February 5, 2023, the Company delivered written notice to Oppenheimer & Co. Inc. (the "Sales Agent") of such termination, issuable pursuant to the Equity Distribution Agreement, dated August 20, 2021, by and between the Company and the Sales Agent (the "Equity Distribution Agreement"). The Company will suspend the sale of the ATM Shares pursuant to the Equity Distribution Agreement, unless and until a new prospectus supplement is filed. Other than the termination of the ATM Prospectus Supplement and suspension of the sale of the ATM Shares under the Equity Distribution Agreement, the Equity Distribution Agreement remains in full force and effect.

A copy of the Equity Distribution Agreement was filed as Exhibit 1.1 to the Company's Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission on March 30, 2022.

***Focus on Next Generation Chemotherapy/Suspension of Further Enrollment in PCS499 Trials***

 ****

Consistent with the shift in priority, including the allocation of resources to Next Generation Chemotherapy drugs, the Company intends to suspend further enrollment in the PCS499 trial for ulcerative Necrobiosis Lipoidica. The Company has begun and will continue to meet with potential licensing partners, as well as consider other options to monetize PCS12852 and PCS499. As previously reported, the clinical study findings for PCS12852 were positive in gastroparesis patients. There were no safety concerns during the conduct of either study, and the Company continues to believe that PCS499 could be effective in treating other ulcers, including less rare indications for PCS499 such as chronic venous ulcers and intermittent claudication.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | Processa Pharmaceuticals, Inc. | Processa Pharmaceuticals, Inc. |
| Date: | February 6, 2023 | By: | */s/ David Young* |
|  |  |  | David Young Chief Executive Officer |

---